重组人血管内皮抑制素注射液放疗增敏作用机制的研究进展

Research Progress in Mechanisms of Recombinant Human Vascular Endostatin Injection on Radiosensitization

重组人血管内皮抑制素注射液(商品名:恩度)是由我国科学家自主研发的新一代抗血管生成药物,大量基础及临床研究均证实了恩度具有放疗增敏作用。恩度与放疗的联合应用可增强恶性肿瘤的治疗效果,可能的放疗增敏机制主要包括提供血管正常化时间窗、下调促血管生成因子、使细胞周期阻滞于放疗敏感期、诱导细胞凋亡以及改善肿瘤微环境等。期待未来恩度更深层次的作用机制得以揭示,为抗血管生成治疗与其他治疗策略的联合提供理论依据,为肿瘤患者带来更精准的医疗决策和更长远的生存获益。

Recombinant human endostatin injection(Endostar)is a new generation of anti-angiogenic drug independently developed by China.Basic and clinical studies have confirmed that Endostar can enhance the sensitivity of radiotherapy.The combination of Endostar and radiotherapy is able to improve the curative effect of malignant tumors.Current researches believe that the possible mechanisms of Endostar′s radiosensitization mainly include providing a time window for blood vessel normalization,down-regulating angiogenic factors,blocking the cell cycle in radiotherapy-sensitive periods,inducing cell apoptosis and improving the tumor microenvironment.It is expected that the disclosure of deeper mechanisms can provide theoretical basis for the combination of anti-angiogenesis therapy and other treatments,bringing more precise medical strategies and longer-term survival benefits for the tumor patients.